We are live on ! Find out more
HEPA

Hepion Pharmaceuticals
HEPA

Delisted

HEPA was delisted on the 12th of May, 2025.

Back to rankings

15 hedge funds and large institutions have $4M invested in Hepion Pharmaceuticals in 2023 Q3 according to their latest regulatory filings, with 1 funds opening new positions, 2 increasing their positions, 4 reducing their positions, and 2 closing their positions.

New
Increased
Maintained
Reduced
Closed

6% less funds holding

Funds holding: 16 → 15 (-1)

26% less capital invested

Capital invested by funds: $5.43M → $4M (-$1.43M)

50% less first-time investments, than exits

New positions opened: 1 | Existing positions closed: 2

50% less repeat investments, than reductions

Existing positions increased: 2 | Existing positions reduced: 4

Holders
15
Holders Change
-1
Holders Change %
-6.25%
% of All Funds
0.24%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
1
Increased
2
Reduced
4
Closed
2
Calls
$21K
Puts
–
Net Calls
+$21K
Net Calls Change
-$25K

Top Buyers

Rank Fund Capital Flow
1
AC
Armistice Capital
New York
+$2.97M
2
Osaic Holdings
Osaic Holdings
Arizona
+$16.4K
3
TRCT
Tower Research Capital (TRC)
New York
+$14.6K

Top Sellers

Rank Fund Capital Flow
1
OCA
Octagon Capital Advisors
New York
-$653K
2
Renaissance Technologies
Renaissance Technologies
New York
-$140K
3
Morgan Stanley
Morgan Stanley
New York
-$76.5K
4
BlackRock
BlackRock
New York
-$20.9K
5
UBS Group
UBS Group
Switzerland
-$19.8K
Name Holding Trade Value Shares
Change 		Change in
Stake
AC
1
Armistice Capital
New York
$1.98M +$2.97M +7,952 New
Vanguard Group
2
Vanguard Group
Pennsylvania
$826K – – –
BlackRock
3
BlackRock
New York
$414K -$20.9K -56 -3%
OCA
4
Octagon Capital Advisors
New York
$337K -$653K -1,750 -56%
Geode Capital Management
5
Geode Capital Management
Massachusetts
$174K – – –
State Street
6
State Street
Massachusetts
$78.2K – – –
Susquehanna International Group
7
Susquehanna International Group
Pennsylvania
$73K – – –
Morgan Stanley
8
Morgan Stanley
New York
$65.3K -$76.5K -205 -44%
Osaic Holdings
9
Osaic Holdings
Arizona
$22.4K +$16.4K +44 +96%
PNC Financial Services Group
10
PNC Financial Services Group
Pennsylvania
$14.4K – – –
TRCT
11
Tower Research Capital (TRC)
New York
$11.1K +$14.6K +39 +780%
Group One Trading
12
Group One Trading
Illinois
$1.69K -$373 -1 -13%
FDCDDQ
13
Federation des caisses Desjardins du Quebec
Quebec, Canada
$873 – – –
Wells Fargo
14
Wells Fargo
California
$140 – – –
Barclays
15
Barclays
United Kingdom
$80 – – –
JP Morgan Chase
16
JP Morgan Chase
New York
$25 – – –
UBS Group
17
UBS Group
Switzerland
$10 -$19.8K -53 Closed
AF
18
Allworth Financial
California
$5 – – –
Bank of America
19
Bank of America
North Carolina
$5 – – –
GRP
20
Global Retirement Partners
California
$5 – – –
HIA
21
Harbor Investment Advisory
Maryland
$5 – – –
S
22
SignatureFD
Georgia
$5 – – –
Renaissance Technologies
23
Renaissance Technologies
New York
– -$140K -267 Closed

HEPA Hedge Fund Activity: Q3 2023 in Review

15 of the 6,301 institutional investors tracked by Wall St. Rank reported a position in Hepion Pharmaceuticals (HEPA) for Q3 2023, worth a combined $4M — down 26% from $5.43M a quarter earlier.

Sellers outnumbered buyers: 2 funds closed out of HEPA and 1 opened new positions — a net loss of 1 holder — while 4 trimmed existing stakes and 2 added.

The largest buyer was Armistice Capital, opening a new position worth an estimated $2.97M. The largest seller was Octagon Capital Advisors, cutting an estimated $653K.

  • 15 institutional investors held Hepion Pharmaceuticals (HEPA) as of Q3 2023, down from 16 in Q2 2023.
  • Funds reported $4M of Hepion Pharmaceuticals stock for Q3 2023, down 26% quarter-over-quarter.
  • 1 fund opened new Hepion Pharmaceuticals positions in Q3 2023 and 2 closed out, a net change of -1 holder.
  • The largest Hepion Pharmaceuticals buyer in Q3 2023 was Armistice Capital, an estimated $2.97M added.
  • The largest Hepion Pharmaceuticals seller in Q3 2023 was Octagon Capital Advisors, an estimated $653K sold.

Based on aggregated 13F filings for Q3 2023.